Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2014 Oct 15;13(12):2784–2792. doi: 10.1158/1535-7163.MCT-14-0593

Table 1.

Summary of CD30 Threshold for Brentuximab Vedotin Efficacy

Baseline CD30 CD30 level at decreased
brentuximab vedotin efficacy
% knockdown
NKL 2.41 1.32 45%
Karpas 299 5.11 2.57 50%
Kem III 1.67 1.14 32%

This table summarizes the absolute amount of baseline CD30 present in each cell line, the amount of CD30 left when brentuximab vedotin efficacy begins to decrease and the percent knockdown that the decrease in CD30 represents. CD30 is measured in ng/µg total cellular protein.